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The correlation between the microdilution
(MD), Etests (ET), and disk diffusion (DD)
methods was determined for amphotericin B,
itraconazole and fluconazole. The minimal
inhibitory concentration (MIC) of those
antifungal agents was established for a
total of 70 Candida spp. isolates from
colonization and infection. The species
distribution was: Candida albicans
(n527), C. tropicalis (n5 17), C. glabrata
(n516), C. parapsilosis (n5 8), and
C. lusitaniae (n52). Non-Candida albicans
Candida species showed higher MICs for
the three antifungal agents when compared
with C. albicans isolates. The overall con-
cordance (based on the MIC value obtained
within two dilutions) between the ET and
the MD method was 83% for amphotericin B,
63% for itraconazole, and 64% for fluconazole.
Considering the breakpoint, the agreement
between the DD and MD methods was 71%
for itraconazole and 67% for fluconazole. The
DD zone diameters are highly reproducible and
correlate well with the MD method, making
agar-based methods a viable alternative to MD
for susceptibility testing. However, data on
agar-based tests for itraconazole and ampho-
tericin B are yet scarce. Thus, further research
must still be carried out to ensure the
standardization to other antifungal agents.
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INTRODUCTION
Fungal hospital infections (FHI) incidence has in-
creased signiﬁcantly over the last decades. Yeasts
from Candida genus are the most frequently isolated
fungi, corresponding to 80% of FHI and being the
fourth microbial agent responsible for blood stream
infection (1–3).
Until some years ago, Candida albicans was the
Candida species that held the most clinical attention.
However, in parallel with the overall increase of fungal
infections it has been observed that non-Candida
albicans Candida (NCAC) species infections are emer-
ging. C. tropicalis, C. glabrata, C. parapsilosis, C. krusei,
C. guilliermondii, and C. lusitaniae (2,4,5) are the most
prominent hospital isolated NCAC species. The reasons
for this alteration in the pattern of Candida species
distribution has not yet been completely understood but
could be attributed to the resistance of those micro-
organisms to antifungal agents and their high use for
relatively long periods during hospitalization (2,6,7).
For this reason, it is of major importance to monitor the
susceptibilities of isolates recovered from compromised
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patients in order to determine strains decreased suscept-
ibilities. The development of standardized antifungal
susceptibility testing methods has been the subject of
numerous studies during the last decade. Thus, the Clinical
and Laboratory Standards Institute (CLSI) developed
several reference methods, including for yeasts M27-A2
method (8,9). However, in order to do this in a cost-
effective way, simple and inexpensive testing procedures are
needed, which must be accurate and precise (10,11).
Agar-based susceptibility testing methods have been a
focus of interest for many researchers and include the
classical disk diffusion (DD) method and the Etests
(ET) method (10,12–14). Those tests are very attractive
owing to their simplicity, reproducibility, and lack of
requirements for specialized equipment (15). Thus, this
work aims to examine Candida susceptibility proﬁle by
applying three different techniques for studying anti-
fungal resistance of C. albicans isolates and NCAC
species in a hospital. Moreover it is also a goal to
compare the susceptibility of Candida isolates obtained
from colonization and infection.
MATERIALS AND METHODS
Hospital
This study was performed at the University Hospital
(UH) of Maringa´, Parana´, Brazil, which is a school
hospital with 116 beds, including an Ambulatory,
Emergency Room, Intermediate Centre, Intensive Care
Unit (ICU), and Semi ICU. UH attends users of the
public health system from Maringa´ and others munici-
palities of the 15th Regional Health Centre of Parana´.
Candida Isolation and Identification
Yeasts were isolated from July 2006 to June 2007. The
samples were classiﬁed in two groups: isolates from
infections (INFEC) and from colonization (COL).
INFEC isolates were obtained from urine cultures
(40) and from blood cultures (7), from all patients
admitted to the ICU and presenting Candida infection
symptoms. Isolates from urine were considered from
infection following the Centre for Disease Control and
Prevention deﬁnitions (16). Accordingly, Candiduria
was considered to be established when the presence of
Candida species in urine cultures was higher than
105CFU/ml (in the absence of bacteria). Moreover,
for patients with urinary catheters, the urine was
collected after 24 hr of the device exchange.
Urine samples were spread by calibrated loop (10 mL)
on CLED medium (Difco, Detroit, Michigan). Hemo-
culture samples were cultured suspending one volume of
blood in ten volumes of trypticase soy broth (Difco) and
then incubated in the automatic BACTEC (Becton
Dickinson Microbiology Systems, Sparks, MD) system.
Viable yeasts were subcultured on Sabouraud dextrose
agar medium (SDA, Difco) at 371C for 48–72 hr.
COL isolates were obtained from the hands of UH staff
members (9), and from central venous catheters (CVCs)
(14). The COL yeasts were isolated following the methods
described by Bonassoli et al. (17) and Maki et al. (18).
After yeast growth, they were subcultured in CHRO-
Magar Candidas (CHROMagar BioMerisc, Paris,
France) to assess the purity of the culture and the color
of the colonies. Yeasts grown in this selective and
differential media were identiﬁed macroscopically, micro-
scopically and physiologically according to Kurtzman
and Fell (19). All samples were cultivated in SDA for
24hr at 37oC before being assayed and were kept in the
Mycology Section of the Microbiology Department of
the Biomedical Sciences Institute of Sa˜o Paulo in Brazil.
Antifungal Susceptibility Test
Microdilution method
Reference antifungal susceptibility testing of Candida
spp. was performed using the microdilution (MD)
method described in CLSI M27-A2 (8).
Reference powders of ﬂuconazole (Pﬁzer Inc. New
York, New York), itraconazole (Janssen Pharmaceutical)
and amphotericin B (Squibb Pharmaceutical) were used.
Stock solutions were prepared with a concentration 10
fold the ﬁnal concentration and diluted with RPMI 1640
(Sigma, St. Louis, Missouri), with L-glutamine, without
bicarbonate, supplemented with 2% dextrose and buf-
fered to pH 7.0 with 0.165 N-morpholinopropanesulfonic
acid (MOPS) to obtain twice the ﬁnal concentration.
ET method
ET strips were provided by AB BIODISK (Solna,
Sweden), with concentrations ranging from 0.002 to
256 mg/ml for ﬂuconazole and from 0.002 to 32 mg/ml for
itraconazole and amphotericin B.
Cells grown in SDA were suspended in saline solution
(0.9%) and the turbidity was adjusted to 0.5 in a
McFarland scale (1 106 to 5 106 cells/ml) before in-
cubation at 371C for 48hr. Then a swab was immersed in
the suspension spread on a RPMI 1640 (American
Biorganics Inc. Buffalo, New York) supplemented with
1.5% agar and 2% glucose, and buffered withMOPS plate.
The minimal inhibitory concentrations (MICs) of drugs
were read asthe lowest concentration at which the border of
the elliptical inhibition zone intercepted the scale of the
strip. Any growth, such as microcolonies, throughout a
discernible inhibition ellipse was ignored. MIC interpreta-
tive criterion was performed according to the CLSI M27-
A2 (8). Brieﬂy, ﬂuconazole: MICr8mg/ml—susceptible
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(S), 16oMICo32mg/ml—susceptible-dose dependent (S-
DD), and MICZ64mg/ml—resistant (R); Itraconazole:
MICr0.125mg/ml—S, 0.25oMICo0.5mg/ml—S-DD,
and MICZ1mg/ml—R; Amphotericin B: MIC41mg/
ml—R.
DD method
DD testing of ﬂuconazole, itraconazole, and ampho-
tericin B was performed as described by Barry et al. (14)
and CLSI document M44-A (20). Fluconazole (25 mg),
itraconazole (10 mg), and amphotericin B (100 mg) disks
were obtained from CECON—Centro de Controle e
Produtos para Diagno´stico, LTDA (Sa˜o Paulo, Brazil).
Plates containing Mueller–Hinton agar (Difco) supple-
mented with 2% glucose and methylene blue (0.5 mg/ml)
were inoculated and incubated as described for the ET
method. After cultivation, the inhibitory diameter zone
(dz) was measured with a ruler. The interpretive criteria
for the ﬂuconazole disk test were those published by
Barry et al. (14) and the CLSI M44 A (20):
dzZ19mm—S; 15odzo18mm—S-DD; dzr14mm—
R. The response to the other antifungal agents was
interpreted according to the manufacturer’s instruc-
tions, Itraconazole: dzZ20mm—S, 12odzo19mm—S-
DD, dzr11mm—R; Amphotericin B: dzr10mm—R.
A quality control was performed in all tests in
accordance with the CLSI document M27-A2 (8) by
using C. krusei ATTC 6258 and C. parapsilosis ATCC
22019. These species were included in all runs, and all
results were within published limits (14).
Analysis of results
The MIC values from ET and MD were considered in
agreement when they were no more than two serial ten
times dilutions apart. The interpretive breakpoints of ET
and DD obtained were used to determine the categorical
agreement in comparison to the results of the reference
MD method for amphotericin B, ﬂuconazole, and
itraconazole. Major errors, were deﬁned when, for the
same isolate, it was obtained a classiﬁcation of R in DD
or ET methods and a classiﬁcation of S in MD method.
Very major errors were deﬁned when a result of S in the
DD or ET methods corresponded to R in the MD
method. Minor errors were deﬁned when a result of S or
R was obtained in one of the tests and a result of S-DD
in the other method (21). Amphotericin B does not have
intermediate category established for CLSI M27-A2.
Statistical analysis
Comparison of MIC obtained with the three methods
was performed using the Mann–Whitney U-test, at 95%
conﬁdence level.
RESULTS
A total of 70 Candida spp. isolates (Table 1) were used
in this study, with 33% obtained from colonization and
67% from infection (candiduria or candidemia) in the
UH of Maringa´, Parana´, Brazil. NCAC species were
predominant in relation to C. albicans corresponding to
61% of the isolated yeasts. Moreover, C. tropicalis and
C. glabrata were identiﬁed in the same extent and were
more prevalent than the other NCAC species.
Considering the ET method (Table 2), amphotericin
B was the only antifungal agent that showed MIC
values under the reference limit (o1 mg/ml) for all
isolates except for one C. albicans (MIC5 32) and
one C. glabrata (MIC5 6). All tested strains, when
assessed by ET, presented higher MICs compared
with MD for ﬂuconazole, itraconazole, and amphoter-
icin B, although this difference was not statistically
signiﬁcant.
Comparing isolates from colonization and infection it
is possible to see (Table 2) that COL yeasts were more
susceptible to the three drugs than INFC yeasts in the
ET method, showing signiﬁcant differences concerning
amphotericin B (Po0.0001) and itraconazole
(P5 0.001). Although, NCAC species had higher MICs
for ﬂuconazole and itraconazole in the MD method
compared with C. albicans MICs, the difference was not
statistically signiﬁcant. Moreover, NCAC species
showed smaller inhibitory zone diameters (DD) for the
three antifungal agents in relation to C. albicans
(Po0.05). In the three methods studied itraconazole
was the antifungal agent with the highest number of
resistant NCAC species.
Table 3 shows that the overall concordance (based
on the MIC value obtained within two dilutions)
between the ET and MD methods was 83% for
amphotericin B, 63% for itraconazole, and 64% for
ﬂuconazole. Considering the breakpoint, ET and
DD methods had high categorical agreement for the




Yeast Hand Catheter Urine Blood Total
C. albicans 2 6 16 3 27
C. tropicalis 2 3 11 1 17
C. glabrata 1 1 11 3 16
C. parapsilosis 3 3 2 0 8
C. lusitaniae 1 1 0 0 2
Total 9 14 40 7 70
326 Negri et al.
J. Clin. Lab. Anal.
three antifungal agents. Although DD method showed
the highest concordance with MD (71%) for itracona-
zole, this method presented a very major discrepancy
rate (4%) for this agent (C. albicans two isolates and
C. glabrata one isolate).
DISCUSSION
Several risk factors are associated with the occurrence
of FHI, among which are the wide use of antimicro-
bial agents, yeast cross-colonization from the hands
of health professionals and use of catheters (2).
TABLE 2. In Vitro Susceptibility of Candida spp. Isolates Obtained From Colonization (COL) or Infection (INFEC) to




COL INFEC COL INFEC COL INFEC
Antifungal agent Rangea Rc Rangea Rc Rangea Rc Rangea Rc Rangeb Rc Rangeb Rc
C. albicans (27)
Fluconazole 0.125–0.5 0 0.25–32 0 0.032–Z256 1 0.094–Z256 8 15–40 0 12–42 1
Itraconazole o0.030–1 1 0.03–4 1 0.004–Z32 1 0.008–Z32 7 20–32 0 11–29 1
Amphotericin B 0.03–0.125 0 0.06–0.5 0 0.016–0.5 0 0.004–Z32 1 19–35 0 17–28 0
C. tropicalis (17)
Fluconazole 0.5–0.5 0 0.125–8 0 0.25–1.5 0 0.125–Z256 1 20–25 0 09–28 2
Itraconazole o0.03–0.25 0 0.06–1 2 0.01–0.5 0 0.023–Z32 3 15–26 0 07–28 2
Amphotericin B 0.03–0.125 0 0.06–0.5 0 0.003–0.25 0 0.47–1 0 25–17 0 12–21 0
C. glabrata (16)
Fluconazole 2–8 0 0.5–16 0 0.25–32 0 2–16 0 20–25 0 13–25 0
Itraconazole 0.06–0.125 0 0.06–4 6 0.012–0.5 1 0.094–32 11 12–20 0 01–20 6
Amphotericin B 0.03–0.03 0 0.06–0.25 0 0.004–1 0 0.064–6 1 16–23 0 15–36 0
C. parapsilosis (8)
Fluconazole 0.25–2 0 2–4 0 0.047–32 0 32–32 0 09–32 0 15–19 1
Itraconazole o0.03–0.125 0 0.5–1 1 0.004–0.25 0 8–24 2 22–35 0 15–10 1
Amphotericin B 0.03–0.125 0 0.5 0 0.002–0.038 0 0.19–0.38 0 14–20 0 20–15 0
C. lusitaniae (2)
Fluconazole 1–4 0 – – 6–8 0 – – 09–25 1 – –
Itraconazole 0.015–0.06 0 – – 0.002–0.25 0 – – 20–24 0 – –
Amphotericin B 0.06–0.125 0 – – 0.032–0.19 0 – – 19–30 0 – –
aValues expressed in micrograms per millilitre (MD and ET).
bValues expressed by inhibitory zone diameter in millimetres (DD).
cNumber of resistant isolates.
TABLE 3. Percentages of Isolates Distributed by Susceptibility Category (% Isolates) and ET or DD Discrepancy Compared to
MD (% discrepancy)
% Isolates % Discrepancy
Antifungal Method S SDD R Minor Major Very major % Categorical agreement % Agreement2 dilution steps
Fluconazole MD 97 3 0
ET 70 16 14 16 13 0 71 64
DD 73 20 7 24 7 0 67 –b
Itraconazole MD 57 27 16
ET 30 33 36 31 10 0 57 63
DD 61 26 13 21 3 4 71 –b
Amphotericin B MD 100 –a 0 –a
ET 97 –a 3 –a 3 0 97 83
DD 100 –a 0 –a 0 0 100 –b
Percentage of isolates classiﬁed in same ET and DD category as the MD reference method (% categorical agreement and agreementr2 dilution
steps).
aNot applicable since no intermediate category is deﬁned.
bNot applicable.
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Nosocomial dissemination of Candida species have
similar routes to other pathogens, such as the transient
carriage on the hands of the hospital staff followed by
colonization or infection of patients and the involve-
ment of the environment as a reservoir (22).
In a total of 70 Candida spp. isolated in the UH of
Maringa´ (Table 1), 13% were obtained from coloniza-
tion of the hands of health professionals; 20% from
colonization of central venous catheters and 67% were
found in patients with candiduria or candidemia. It is
well known that yeast-colonization of health profes-
sional’s hands can be a source of infection by
translocation of those microorganisms to the patient,
when handling or even by contamination of catheter
surface (6,23). Thus, it is possible to understand why the
major cause of Candida spp. infection is reported on
critical patients admitted in ICU (2,22,24).
During the last decades the number of Candida spp.
hospital infections has highly increased becoming the
fourth most common infection pathogens in ICU; it has
also been observed a signiﬁcant increase in morbidity
and mortality of patients who developed FHI (4,24). In
this study it was observed (Table 1) that a high
prevalence of Candida spp. recovered from candiduria,
85.11% of infected patients and only 14.89% from
candidemia. Candiduria cases are increasing especially
among ICU hospitalized patients, who undergo in
prolonged use of urinary catheter or broad spectrum
antibiotics (25). Furthermore, several studies show that
this scenario can be signiﬁcantly associated with
candidemia, thus increasing even more the risk factor
for developing complicated infections (26).
As summarized in Table 1, NCAC species were
predominant (61%) in relation to C. albicans (39%).
According to Krcmery and Barnes (27), NCAC species
are emerging as both colonizers and pathogens causing
nosocomial fungal infections and are responsible for
approximately 50% of fungal infections in ICU patients.
In fact, Matsumoto et al. (5) isolated yeasts from blood
and catheters of hospitalized children (0 to 7 years old)
and observed that NCAC species were predominant.
The increase in NCAC species frequency is probably
owing to the selection of species that are less susceptible
to the most commonly used therapeutic antifungal
agents. Species-speciﬁc differences clearly exist in the
susceptibility to ﬂuconazole and other antifungal agents,
and may be signiﬁcant for the emergence of NCAC
species in some institutions (2,4,28,29).
Furthermore, NCAC species showed higher MICs
than C. albicans for ﬂuconazole and itraconazole (MD
method). However, regarding amphotericin B, all
isolates showed similar MICs, irrespective of the method
employed, except two isolates when assessed by ET: one
C. albicans (MIC5 32) and one C. glabrata (MIC5 6).
Several studies (26,27) showed that usually NCAC
species isolates present resistance to two or three
antifungal agents, and some species, such as C. tropicalis
and C. lusitaniae have inherent or secondary resistance
to ﬂuconazole. Moreover, other NCAC species behave
as C. albicans and are more susceptible to azole
antifungal agents (26,27).
Usually, C. albicans antifungal susceptibility can be
predicted with accuracy but, in contrast, such prediction
is not possible when NCAC species are concerned (27).
Agar-based susceptibility tests such as the traditional
DD and ET commercial methods have been the focus of
interest of many researches (10,12–14). Those methods
enable in vitro antifungal susceptibility determination
and have shown excellent beneﬁts such as technical
simplicity, easy handling, quick results, and overcoming
the use of costly and specialized equipment (13,15).
In this study the interpretative categorical agreement
(Table 3) for ET method compared with MD reference
method showed 71% for ﬂuconazole, 57% for itraco-
nazole, and 97% for amphotericin B. However
the agreement, considering two fold dilutions, between
the ET and MD were different: 64% for ﬂuconazole,
63% for itraconazole, and 83% for amphotericin B.
The differences achieved, considering categories (S, S-
DD and R) or MIC in two different dilutions, can be
owing to the differences in the range considered for ET
andMD. For instance, for amphotericin B the MIC range
in MD is 0.03–0.5mg/L and in ET is 0.002–Z32mg/L,
leading to some disagreement of MICs within the
‘‘susceptible’’ group. This was also veriﬁed by other
authors (10,14) who also compared agar-based methods
with the MD reference method. Although the results
obtained by both DD and ET methods were in
acceptable concordance with those obtained by the
MD method, the detection of resistance by agar-based
methods correlates poorly with the detection of S-DD
by the reference NCCLS M27-A2 method. Speciﬁcally,
for ﬂuconazole, some ‘‘false resistance’’ cases (major
errors) were obtained with ET. Conversely, only 4% of
the isolates that were classiﬁed as resistant by the MD
method appeared to be susceptible when they were
tested by DD method. This difference was principally
owing to trailing growth associated with the MD
method (8,9).
Recent studies have been showing that susceptibility
tests, performed with both DD and ET methods, were just
as reproducible as the results of the standard reference
MD procedure (10,14,30). Furthermore, Pfaller et al. (21)
studied ﬂuconazole susceptibility of C. glabrata and
considered a high agreement between agar-based and
MD methods, with 64.7 and 52.3%, respectively for DD
and ET. This can be explained by the level of proximity
between susceptible and S-DD classiﬁcation (14,21).
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Based on these results and according to data provided
by other studies (10,13,21,31), it is possible to highlight
that ET and DD methods are useful for the determina-
tion of ﬂuconazole resistance, but are not so reliable
for differentiation between susceptible and S-DD
yeast cells. Furthermore, it is known that the most
important objective in the application of these methods
is to detect antifungal resistance. Thus, both methods
(ET and DD) can be extremely useful for such
determination (9). However, concerning drugs as
itraconazole and amphotericin B, data on agar-based
tests are still scarce (10).
Currently, in vitro susceptibility tests can allow very
important guidelines for candidiasis treatment, but the
standard susceptibility test (CLSI M27-A2) is not
always readily available in regular laboratories and is
very time consuming, in opposition to the other more
simple techniques such as ET and DD. The major
feature of these agar-based tests is that they can allow a
quick answer concerning Candida resistance to anti-
fungal agents, preventing unnecessary patients drug
abuse (13,21). In 2003, CLSI published a speciﬁc
standard for DD testing of ﬂuconazole (M44-A), which
increases the possibility of implementing it in all routine
laboratories. However, further research must still be
carried out to ensure the standardization of this method
for other antifungal agents.
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